Conference Reports for NATAP

Back

The International Liver Congress™ EASL - European Association for the Study of the Liver Aug 27-29 Digital ILC 2020     Very Low Rates of Receiving Antiviral Therapy Among Treatment - Eligible Chronic Hepatitis B Virus Infected Patients - (03/04/21)   Obeticholic Acid Demonstrates Sustained Improvements at Month 24 in Transaminases and Non-invasive Markers of Fibrosis: Results of a Post Hoc Analysis From the Interim Analysis of the REGENERATE Study - (11/10/20)   Real-life experience of direct acting antiviral treatment for chronic hepatitis C infection in adolescent patients in a low prevalence setting - (09/28/20)   Microelimination & Elimination at EASL 2020 - (09/28/20)   EDP-297, a novel and potent fxr agonist, exhibit robust anti- fibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis - (09/28/20)   A novel FXR agonist EDP-297 exerts anti-inflammatory and hepatoprotective effects in human liver 3D microtissues and in rodent models of liver injury and NASH - (09/28/20)   EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects - (09/28/20)   Development of a Highly Sensitive Multiplex Platform Assay to Monitor Low Levels of HBV DNA and pgRNA - (09/28/20)   Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positive chronic hepatitis B infection in a long-term extension study - (09/28/20)   Antiviral activity, pharmacokinetics, and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in a phase 1b study of patients with HBeAg positive chronic hepatitis B infection - (09/28/20)   A multidisciplinary approach to non-alcoholic fatty liver disease (NAFLD) improves cardiovascular risk factors - (09/25/20)   Progression of liver stiffness and the development of cirrhosis in histologically characterized patients with nonalcoholic fatty liver disease - (09/25/20)   Optimal Non-Invasive Screening Strategy for Nonalcoholic Fatty Liver Disease in a Prospective Cohort of Patients with Type 2 Diabetes - (09/25/20)   Associations Between Serum Bile-Acid Species With Liver Fibrosis and Prognosis in Patients With Primary Sclerosing Cholangitis - (09/23/20)   Machine Learning Models Accurately Interpret Liver Histology and Are Associated With Disease Progression in Patients With Primary Sclerosing Cholangitis - (09/23/20)   Hepatic Transcriptomic Analysis Identifies a Mast Cell Gene Expression Signature That Correlates With Fibrosis Stage and Is Prognostic in Patients With Primary Sclerosing Cholangitis - (09/23/20)   Removal of Fibrosis-Related Genes Identifies a Hepatic Gene Expression Signature That Identifies Canonical Signaling Pathways and Is Correlated With Clinical Outcomes in Patients With Primary Sclerosing Cholangitis - (09/23/20)   Hepatitis C infection in the Spanish Prison System. Elimination is a dream at our fingertips - (09/23/20)   Treatment of hepatitis C at the Stockholm needle exchange program - treatment success, reinfection rates and challenges for HCV elimination - (09/23/20)   Serum and intrahepatic HBV markers and HBV-specific CD8 T cell responses after nucleos(t)ide analog therapy discontinuation in HBeAg-negative chronic hepatitis B patients - (09/23/20)   Real-world efficacy and safety of direct-acting antivirals in patients with liver cirrhosis and history of hepatic decompensation: Epi-Ter2 Study. - (09/21/20)   HEALTH-RELATED QUALITY OF LIFE (HRQOL) BEFORE AND AFTER TREATMENT OF GENOTYPE 1 (GT1) INFECTION WITH ELBASVIR/GRAZOPREVIR (EBR/GZR): RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (09/21/20)   Impact of universal access to direct-acting antivirals in the profile of the Hepatitis C treated patient - (09/21/20)   INNOVATIVE PROCEDURES FOR MICRO-ELIMINATION OF HCV INFECTION IN A HIGH-RISK POPULATION OF UNDOCUMENTED MIGRANTS AND LOW-INCOME REFUGEES - (09/21/20)   Direct-acting antiviral treatment in patients infected with a nonepidemic hepatitis C genotype in the Netherlands: results from a nationwide cohort study - (09/21/20)   The dynamics of FIB4 after sustained viral response predicts the risk of liver-related complication in HCV cirrhosis (ANRS CO12 CirVir) - (09/21/20)   GES score: A simple score for HCC risk stratification in CHC patients with cirrhosis who achieved SVR following DAAs - (09/21/20)   The English hepatitis C registry shows only a modest effect from non- completion of directly-acting antivirals for hepatitis C: SVR rates over 80% in genotype 1, 2 or 3 HCV if more than one third of planned treatment is complete - (09/21/20)   Cotadutide Tames Metabolic Markers in Overweight/Obese With Diabetes - Mark Mascolini - (09/17/20)   Novel markers to predict virological and clinical relapse onset following antiviral treatment discontinuation in chronic hepatitis B patients - (09/17/20)   A Once-per-week or Every-two-week Dosing Regimen is More Efficacious for the TLR7 Agonist JNJ-64794964 (JNJ-4964) to Induce an Anti-hepatitis B Virus (HBV) Effect and HBV-specific Immune Responses in AAV-HBV Mice - (09/17/20)   Efficacy and Safety Results of the Phase 2 JNJ-56136379 JADE Study in Patients with Chronic Hepatitis B: Interim Week 24 Data - (09/17/20)   Characterization of Serologic Responses Following ALT Flares in >3000 CHB Patients Pooled from 5 Clinical Trials - (09/17/20)   Analysis of HBsAg levels, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and REP 401 studies - (09/17/20)   Resistance monitoring data from treatment-naïve chronic HBV infected patients treated for 28 days with a new Class A core protein allosteric modulator RO7049389 monotherapy - (09/17/20)   EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Resultsof a Phase 1 Study in Healthy Adult Subjects - (09/17/20)   Better Survival With TDF Than Entecavir After Hepatectomy for HCC: "Tenofovir vs entecavir on post-operative recurrence-free and overall survival of patients with hepatitis B virus-related hepatocellular carcinoma" - Mark Mascolini (09/16/20)   Safety and Efficacy of Switching to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Renal Impairment: Week-48 Results From a Phase 2 Open-label Study - (09/16/20)   Safety and Efficacy of Switching to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Hepatic Impairment: Week-48 Results From a Phase 2 Open-label Study - (09/16/20)   Safety and Efficacy of Tenofovir Alafenamide in Geriatric Patients With Chronic Hepatitis B: Experience From 4 Ongoing Phase 2 and Phase 3 Clinical Trials - (09/16/20)   Updated Estimate for Prevalence of Chronic Hepatitis B Among Foreign-Born Persons Living in United States by Country of Origin - (09/16/20)   Serum and intrahepatic HBV markers and HBV-specific CD8 T cell responses after nucleos(t)ide analog therapy discontinuation in HBeAg-negative chronic hepatitis B patients - (09/16/20)   Transcriptome Analysis of Paired Liver Biopsies Identifies Correlates of HBsAg Response in Placebo- and TDF-treated CHB Patients - (09/16/20)   Can More People Stops NRTIs for HBV? Hints From a 48-Week Study - Mark Mascolini (09/16/20)   HBV Reactivation Rare in HBV Patients Who Used Immune Checkpoint Inhibitors - Mark Mascolini (09/16/20)   A Phase 3 Study Comparing Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Final Week 96 Efficacy and Safety Results - (09/16/20)   Preliminary safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in chronic hepatitis B patients - (09/16/20)   THERATECHNOLOGIES TO DEVELOP TESAMORELIN FOR THE TREATMENT OF NASH IN THE GENERAL POPULATION - (09/15/20)   Myosteatosisis strongly associated with NASH in humans and in preclinical NAFLD models - (09/15/20)   Machine learning to predict recurrence of early-stage HCC before therapy using baseline MRI - (09/15/20)   Glympse Liver Test for Noninvasive Monitoring of Combination Drug Therapy in a Rat Model of Nonalcoholic Steatohepatitis - (09/15/20)   The Pharmacokinetics, Pharmacodynamics, and Short-term Safety of Cilofexor, a Nonsteroidal Farnesoid X Receptor Agonist, in Subjects With Hepatic Impairment - (09/15/20)   Concentration-QT Analysis of Firsocostat, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor - (09/15/20)   Improvements in the ELF Test Are Associated With Widespread Changes in the Hepatic Transcriptome in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (09/15/20)   Machine Learning Models Identify Novel Histologic Features Predictive of Clinical Disease Progression in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (09/15/20)   Predictive modelling to identify and characterize fast progressors among patients with non-alcoholic steatohepatitis (NASH) - (09/15/20)   Europe's largest meta-analysis on the prevalence of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and advanced fibrosis (F3-F4) - (09/15/20)   Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with nonalcoholic steatohepatitis - (09/15/20)   Association of FIB4 score with disease progression in real -world populations diagnosed with NAFLD/NASH or at risk of NASH in US Clinical Practice - (09/04/20)   Phenome-Wide Association Study of the FIB-4 Index in a Large, Population-Based Study in the United States - (09/04/20)   The Safety and Pharmacokinetics of Fenofibrate in Patients With Advanced Fibrosis, Including Those With Nonalcoholic Steatohepatitis - (09/04/20)   Combination of an Acetyl CoA Carboxylase Inhibitor With Therapeutics That Promote Fatty-Acid Oxidation Does Not Improve Antifibrotic Efficacy in a Preclinical NASH Model - (09/04/20)   Efficacy and Safety of an Acetyl CoA Carboxylase Inhibitor Are Improved in Combination With PPAR Agonists in a Dyslipidemic Rat Model - (09/04/20)   A Phase 2 Dose Ranging, Randomized, Double-blind and Placebo-Controlled Study of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH) - (09/04/20)   Liver disease progression and clinical outcomes in the Hepatic Outcomes and Survival Fatty liver Registry (HOTSURFR) Study - (09/04/20)   Proton Beam Radiotherapy Noninferior to Radiofrequency Ablation for HCC - Mark Mascolini (09/04/20)   Adherence & DAAs: how much is necessary to Achieve SVR: 75% in 1 study Achieves SVR & 50% in 2nd Study Achieves >90% SVR rate - (09/04/20)   Screening and treatment difficulties of hepatitis C virus infected patients with substance use disorders or dual pathology, despite centralized management in an addiction and dual diagnosis center - (09/04/20)   HIV co-infection and risk of morbidity and mortality in HCV patients treated by DAA After DAAs for HCV, Liver Events and Liver Mortality Not Affected by HIV - Mark Mascolini (09/04/20)   Direct-acting antivirals have substantially modified the profile of patients with cirrhosis who require hospitalization in Spain - Mark Mascolini (09/04/20)   Noninvasive Tests of Fibrosis and Risk of Liver-Related Complications: Lessons From Patients With HCV Cirrhosis Following Successful Sofosbuvir-Based Treatment - (09/04/20)   Risk of end-stage renal disease among hepatitis C patients with chronic kidney disease treated with and without sofosbuvir - (09/04/20)   Health-Related Quality of Life Among People Receiving Opioid Agonist Therapy and Treatment for Hepatitis C Virus Infection: Results From CO-STAR - (09/04/20)   Development of a Novel Model to Support Elbasvir/Grazoprevir Use in Children With Chronic Hepatitis C Virus Genotypes 1 or 4 Infection - (09/04/20)   Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics - (09/04/20)   Decline in HCV incidence in HIV positive MSM -progress to HCV micro-elimination in the UK? - (09/04/20)   Acute HCV Rate Down 68% in HIV+ UK MSM Since 2015 - Mark Mascolini (09/04/20)   COVID-19 and the liver - data from international registries - (09/04/20)   FXR Agonist EDP-305 Lowers ALT and Liver Fat in NASH - Mark Mascolini (08/31/20)   Nidufexor Lowers ALT and Liver Fat at 12 Weeks in NASH Patients - Mark Mascolini (08/31/20)   TVB-2640 Lowers Liver Fat, Improves Fibrosis, in Phase 2a NASH Trial - Mark Mascolini (08/31/20)   Liver and Heart Disease, Nonsolid Cancers, Lead Causes of Death With NAFLD - Mark Mascolini (08/31/20)   Safety and Efficacy of Combination Therapies Including Cilofexor/Firsocostat in Patients With Bridging Fibrosis and Cirrhosis Due to NASH: Results of the Phase 2b ATLAS Trial (08/31/20)   CCR2/5 Antagonist Plus FGF21 Analog Quell Liver Fat, Fibrosis in Mice - Mark Mascolini (08/31/20)   NASH and Visceral Fat Tied to Adipose IR Independently of BMI - Mark Mascolini (08/31/20)   Despite Evidence of Benefit in NASH, GLP1a and SGLT2i Use Low in US - Mark Mascolini (08/31/20)   More Comorbidities With NAFLD/NASH Than Hepatitis in Global Survey - Mark Mascolini (08/31/20)   Causes of Death in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Data from National Vital Statistics System (NVSS) - (08/31/20)   Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment (08/27/20)   Efficacy and Safety of 24 Weeks Treatment with Oral TLR8 Agonist Selgantolimod (GS-9688, SLGN) in Virally Suppressed Adult Patients with Chronic Hepatitis B: A Phase 2 Study (08/27/20)   Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg negative chronic hepatitis B infection (08/27/20)   Hepatitis B Virus Surface Antigen Inhibition with GSK3228836 (ISIS 505358) in Chronic Hepatitis B Patients on Stable Nucleos(t)ide Analogue Regimen and in Nucleos(t)ide Analogue Naïve Patients: A Phase 2a, Randomized, Double-blind, Placebo-controlled Study (08/27/20)   RO7062931 ANTISENSE OLIGONUCLEOTIDE PHASE 1 STUDY DEMONSTRATES TARGET ENGAGEMENT IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) ON ESTABLISHED NUCLEOS(T)IDE THERAPY (08/27/20)   Multidisciplinary NAFLD Approach Yields Strong CVD Risk Gains - Mark Mascolini (08/27/20)   Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials - (08/27/20)   Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression Vs Men: A Systematic Review and Meta-analysis - (08/27/20)   Global real-world evidence of sofosbuvir/velpatasvir(SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness - (08/27/20)   Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials - (08/27/20)   Efficacy of Sofosbuvir/Velpatasvir (S/V): Impact of Treatment Adherence - (08/27/20)   HCV in the Australian primary care setting: Real-world effectiveness of 12 weeks of sofosbuvir/velpatasvirfor the treatment of chronic hepatitis C - (08/27/20)   Virological characterization of patients with CHC and failure to a glecaprevir/pibrentasvir or voxilaprevir/velpatasvir/sofosbuvir treatment in the international SHARED collaboration - (08/27/20)   Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C - (08/27/20)   New HCV Rate Dropping in German HIV+ MSM-But Reinfection Rate 18% - Mark Mascolini (08/27/20)   Directly observed therapy for hepatitis C with sofosbuvir/velpatasvir alongside opioid substitution as a tailored microelimination strategy in PWIDs with a high risk of nonadherence - real-world data from Vienna, Austria - (08/27/20)   Barriers to Hepatitis C Virus Elimination in Germany: Why Aren't Diagnosed Patients Initiating Therapy? - (08/27/20)   Real-World Clinical Practice Outcomes in Hepatitis C-Infected Patients With Psychiatric and Substance Use Disorders Treated With Glecaprevir/Pibrentasvir for 8 or 12 Weeks: A Pooled Analysis Across 9 Countries - (08/27/20)   Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: evidence of treatment as prevention from the SToP-C study - (08/27/20)   Global timing of hepatitis C virus elimination in high-income countries: an updated analysis - (08/27/20)   Anticipated timing of elimination of hepatitis C virus in Canada's four most populous provinces - (08/27/20)   EARLY TREATMENT OF HEPATITIS C VIRUS IMPROVES HEALTH OUTCOMES AND YIELDS COST-SAVINGS: A MODELING STUDY IN ARGENTINA - (08/27/20)   Integrated Efficacy and Safety Analysis of GT1-6 Treatment-Naïve, Non-Cirrhotic and Compensated Cirrhotic Patients Who Received 8 Weeks of Glecaprevir/Pibrentasvir - (08/27/20)   Timing of Hepatitis C Elimination in the United States: Estimating the year each state will achieve the World Health Organizations targets - (08/27/20)   Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy - (08/27/20)